Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lexeo Therapeutics, Inc. - Common Stock (NQ: LXEO ) 16.04 +1.18 (+7.94%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 28, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 549,809 Open 15.27 Bid (Size) 15.51 (10) Ask (Size) 16.75 (10) Prev. Close 14.86 Today's Range 15.04 - 16.40 52wk Range 9.000 - 22.33 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights May 09, 2024 From Lexeo Therapeutics Via GlobeNewswire Lexeo Therapeutics to Participate in Upcoming Investor Conferences May 07, 2024 From Lexeo Therapeutics Via GlobeNewswire Performance YTD +8.16% +8.16% 1 Month -0.06% -0.06% 3 Month +1.20% +1.20% 6 Month +8.16% +8.16% 1 Year +59.60% +59.60% More News Read More Matterport, Sea Limited, Ingevity And Other Big Stocks Moving Higher On Monday April 22, 2024 Via Benzinga Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy April 22, 2024 From Lexeo Therapeutics Via GlobeNewswire Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy April 16, 2024 From Lexeo Therapeutics Via GlobeNewswire Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing March 13, 2024 From Lexeo Therapeutics Via GlobeNewswire RBC Capital Maintains Outperform Rating for Lexeo Therapeutics: Here's What You Need To Know March 12, 2024 Via Benzinga Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights March 11, 2024 From Lexeo Therapeutics Via GlobeNewswire Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing March 11, 2024 From Lexeo Therapeutics Via GlobeNewswire Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday March 06, 2024 Via Benzinga Topics Stocks Exposures US Equities Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments February 05, 2024 From Lexeo Therapeutics Via GlobeNewswire Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session January 18, 2024 Via Benzinga Fastenal Posts Upbeat Earnings, Joins NovoCure, Taiwan Semiconductor Manufacturing And Other Big Stocks Moving Higher On Thursday January 18, 2024 Via Benzinga Topics Stocks Exposures US Equities Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 From LEXEO Therapeutics Via GlobeNewswire Marathon Digital, Canaan, CleanSpark And Other Big Stocks Moving Lower On Tuesday December 26, 2023 Via Benzinga Topics Stocks Exposures US Equities Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM) December 18, 2023 From LEXEO Therapeutics Via GlobeNewswire LXEO Stock Earnings: Lexeo Therapeutics Reported Results for Q3 2023 December 11, 2023 Via InvestorPlace Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights December 11, 2023 From LEXEO Therapeutics Via GlobeNewswire 12 Health Care Stocks Moving In Friday's After-Market Session December 01, 2023 Via Benzinga Pineapple Financial Drops In Trading Debut November 05, 2023 Via Talk Markets Topics Initial Public Offering Exposures Securities Market Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
